Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of tebapivat in sickle cell disease
2024-519746-70-01Phase 2Authorised
- Sponsor
- Agios Pharmaceuticals
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of tebapivat in sickle cell disease (SCD) (4 arms), sponsored by Agios Pharmaceuticals. Primary endpoint: Hemoglobin response. Planned start Sep 2025; status: authorised.
02
Drugs
tebapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2024-519746-70-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519746-70-01.